https://techcrunch.com/2021/09/09/breakout-crispr-platform-company-mammoth-biosciences-is-officially-a-unicorn/

The CRISPR-based biotech startup Mammoth Biosciences is officially a unicorn, the company says. 

The billion dollar valuation comes on the back of a $150 million series D round led by Redmile Group, with participation from Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, Plum Alley and NFX. Combined with a late 2020 Series C round of $45 million (which included participation from Amazon), this brings the company’s total financing to $195 million.